The Supreme Court of the United States’ decision in United States v. Arthrex, Inc. gives the U.S. Patent and Trademark Office (USPTO) director the right to review Patent Trial and Appeal Board (PTAB) decisions. However, the decision did not provide much guidance on how to ask the director for a rehearing, how this new rehearing step will work alongside the Precedential Opinion Panel, and what will happen with a backlog of cases that were remanded by the U.S. Court of Appeals for the Federal Circuit now that the justices have issued their ruling in Arthrex. Law360 interviewed Finnegan partner Joshua Goldberg for his thoughts on the decision.
Josh indicated that the current lack of a USPTO director could cause some challenges, as the agency is currently led by someone who was not confirmed by the Senate. He said, “Can the acting director even do anything about this, or do we have to wait until there's a fully appointed new director?”
Read “Arthrex Ruling Leaves Attys Eyeing USPTO for Guidance”
Arthrex v. Smith & Nephew , United States v. Arthrex, Supreme Court of the United States (SCOTUS), Patent Trial and Appeal Board (PTAB), administrative patent judge (APJ)
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.